Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer
about
Revisiting the hallmarks of cancer.TCRP1 transcriptionally regulated by c-Myc confers cancer chemoresistance in tongue and lung cancer.Heterotypic mouse models of canine osteosarcoma recapitulate tumor heterogeneity and biological behavior.Coordinating antigen cytosolic delivery and danger signaling to program potent cross-priming by micelle-based nanovaccine.The Unique Molecular and Cellular Microenvironment of Ovarian CancerChemokines in the cancer microenvironment and their relevance in cancer immunotherapy.DNA Damage and Repair Biomarkers of Immunotherapy Response.Metabolic Interactions in the Tumor Microenvironment.The immune contexture in cancer prognosis and treatment.Human cancer-associated fibroblasts enhance glutathione levels and antagonize drug-induced prostate cancer cell death.Biodegradable Hollow Mesoporous Silica Nanoparticles for Regulating Tumor Microenvironment and Enhancing Antitumor Efficiency.Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient.Tumor-infiltrating CD8+ lymphocytes predict different clinical outcomes in organ- and non-organ-confined urothelial carcinoma of the bladder following radical cystectomy.Microenvironmental InterFereNce of metabolism regulates chemosensitivity.Suppression of FIP200 and autophagy by tumor-derived lactate promotes naïve T cell apoptosis and affects tumor immunity.Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor.Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4.Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy.Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.The latest animal models of ovarian cancer for novel drug discovery.Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma.Revisiting ovarian cancer microenvironment: a friend or a foe?Ovarian cancer: how can resistance to chemotherapy be tackled?Immunological hallmarks of cis-DDP-resistant Lewis lung carcinoma cells.Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.Immune Cell Metabolism in Tumor Microenvironment.Phenotype and tissue distribution of CD28H+ immune cell subsets.Targeting the tumour stroma to improve cancer therapy.The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas.The mechanical microenvironment regulates ovarian cancer cell morphology, migration, and spheroid disaggregation.The circadian clock regulates cisplatin-induced toxicity and tumor regression in melanoma mouse and human models.Redox-responsive cisplatin nanogels for anticancer drug deliveryMicroenvironmental regulation of cancer cell metabolism: implications for experimental design and translational studies
P2860
Q33732986-34B4F0BA-8AD0-424A-86DB-5FB095E186F4Q33807765-5A4C4FE5-DF76-4BBE-9E1F-58C5C0A04E13Q37545406-64E1F5E8-F675-47A6-81F3-D6FA5F0D7CB3Q37736868-98E3E5A3-3A2B-41F9-BB8D-7B0660CAC1ABQ39169603-5FCEE8AD-71E7-471E-A8B0-904A64F183E6Q39337489-F588E06C-C1C6-4BEA-9080-5E6A49D3D1F5Q39384263-A32DCAB0-2560-408C-B921-956FABEF443CQ39452100-D575CCDD-A513-4E83-8B6C-809748234641Q39456999-E61D7AE5-1F91-4BE0-A1A4-AB816E92B5E8Q41083985-FCE4A2D6-6AA3-47D3-A6AC-E09114D49449Q41239757-0CF6F433-113C-45A1-AAA8-0B6EF85D7193Q41571576-F464458D-D80C-4FD1-85BF-29989E544953Q42378252-33C6FCA4-7B71-4137-9F51-4A5D3AE05522Q42381317-B6A4DDFC-B1EE-4B5E-8C7C-63F94AE8BC2DQ46259330-CCFE7951-B631-4C4E-A5E9-8968FECB6E4FQ46272404-CE0AF8A7-4539-4AB5-A2BA-C2B314340686Q46304951-D7C9057C-3C40-4F8B-8371-A4A4F730A578Q46329298-CD553C35-768E-48A0-86F2-20465AD1E484Q47344966-7CB6F570-0B18-4B09-AEFD-06E0C0248384Q47553013-0C5F775A-5CEC-41D3-8320-025D8E2C05EEQ47621546-3FA472E9-D9E3-4D34-AD1E-DCC39C0F29ECQ47773956-B557B811-9B3E-443C-822B-630FEB931CA0Q47813897-6ED57CA8-35E6-419C-8D1C-0830560BCB58Q49382862-16AB4313-1755-4BCF-A392-D0229E884BCAQ50031833-BAFBA7D2-F1FA-4772-B0FB-3EE30DE7CC25Q50217783-43CDB8FF-E6BF-487A-82EE-CC68A42BA0F7Q50546758-39ADCEE3-854C-4704-B151-8711CBD48FF6Q52322982-5F705CA4-03A5-41DB-9C76-52AFBB307854Q52592969-1B92DF44-F6F9-4762-9B82-9B02C43C5254Q55287510-7D8923FD-C52C-4AD7-B971-EDFAC3CC41FDQ55318141-B4460BB2-89AD-46B2-95D8-23F664DED4CFQ58355743-91315B13-D82E-4693-93AB-A7C899C6E703Q58796751-48964233-5C0E-4E4A-A19D-7F5E5194377E
P2860
Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer
@en
type
label
Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer
@en
prefLabel
Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer
@en
P2093
P2860
P1433
P1476
Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer
@en
P2093
Adnan Munkarah
Dongjun Peng
Ilona Kryczek
J Rebecca Liu
Jan Kotarski
P2860
P304
P356
10.1016/J.CELL.2016.04.009
P407
P50
P577
2016-04-28T00:00:00Z